Try Ageless Tirzepatide Review

Try Ageless—found at tryageless.com and operated by Lovely Meds, Inc. of Newark, Delaware—is a newer cash-pay GLP-1 telehealth service notable for format flexibility: injections, troches, and daily sublingual drops, with free switching between them. (Don't confuse it with AgelessRx, the separate longevity platform also in our rankings.) Our research (checked July 25, 2026) verified pricing, terms, and disclosures.

Formats and Verified Pricing

All injectable formulations include B12; pricing splits by commitment:

• Compounded semaglutide+B12 injection—from $199/month on yearly plans; $279/month month-to-month
• Compounded tirzepatide+B12 injection—from $249/month yearly; $349/month monthly
• Tirzepatide sublingual drops (daily)—from $159/month yearly; $199/month monthly
• Semaglutide troches and oral drops—offered via product pages (2mg and 6mg troche strengths)

Plans include unlimited messaging, free shipping, and injection supplies. Clinician review runs 24-48 hours with same-day prescriptions in most states and shipment in 3-5 business days in plain packaging.

Consumer-Friendly Terms

Try Ageless publishes the terms many peers hide: cancel anytime with no fees or contracts, pause available, and free format switching through the patient portal—structural protections against the subscription traps common to this category. Payments are HSA/FSA eligible; LegitScript and HIPAA badges are displayed, medications come from state-licensed U.S. 503A pharmacies to USP purity standards, and—credit where due—its pages carry the boxed-warning context for medullary thyroid carcinoma directly.

What to Confirm

Clinicians are described only as licensed U.S. providers—no names—and the pharmacies are unnamed; contact is email/support-form only with no phone. The site cites a 4.9 rating across 3,200+ reviews and a 91% three-month renewal rate—company figures whose verifiable footprint (a modest reviews.io presence with positive early reviews) is far smaller. Ask who prescribes, which pharmacy fills, and confirm your plan tier—yearly-plan rates are the headline numbers.

Critical 2026 Regulatory Context

In 2026 the FDA proposed excluding semaglutide and tirzepatide from the 503B bulks list, restricting mass GLP-1 compounding; Try Ageless sources from 503A pharmacies (patient-specific compounding). Confirm current availability before enrolling.

Important: Compounded Medications

Try Ageless states it plainly: compounded medications dispensed by state-licensed pharmacies are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality. Sublingual and troche GLP-1 formats also lack the clinical-trial evidence base of the branded injectables. Consult your own physician before starting.